MA37765A1 - Composés de pyrazole substitués utilisés comme antagonistes de lpar - Google Patents

Composés de pyrazole substitués utilisés comme antagonistes de lpar

Info

Publication number
MA37765A1
MA37765A1 MA37765A MA37765A MA37765A1 MA 37765 A1 MA37765 A1 MA 37765A1 MA 37765 A MA37765 A MA 37765A MA 37765 A MA37765 A MA 37765A MA 37765 A1 MA37765 A1 MA 37765A1
Authority
MA
Morocco
Prior art keywords
compounds used
pyrazole compounds
substituted pyrazole
lpar antagonists
lpar
Prior art date
Application number
MA37765A
Other languages
English (en)
French (fr)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37765A1 publication Critical patent/MA37765A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA37765A 2012-06-20 2013-06-17 Composés de pyrazole substitués utilisés comme antagonistes de lpar MA37765A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
MA37765A1 true MA37765A1 (fr) 2017-04-28

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37765A MA37765A1 (fr) 2012-06-20 2013-06-17 Composés de pyrazole substitués utilisés comme antagonistes de lpar

Country Status (22)

Country Link
US (1) US20150259295A1 (pt-PT)
EP (1) EP2864294A1 (pt-PT)
JP (1) JP2015520201A (pt-PT)
KR (1) KR20150011003A (pt-PT)
CN (1) CN104411690A (pt-PT)
AU (1) AU2013279510A1 (pt-PT)
BR (1) BR112014031108A2 (pt-PT)
CA (1) CA2869602A1 (pt-PT)
CL (1) CL2014003242A1 (pt-PT)
CO (1) CO7160077A2 (pt-PT)
CR (1) CR20140516A (pt-PT)
EA (1) EA201492283A1 (pt-PT)
HK (1) HK1206341A1 (pt-PT)
IL (1) IL236091A0 (pt-PT)
IN (1) IN2014DN09347A (pt-PT)
MA (1) MA37765A1 (pt-PT)
MX (1) MX2014014105A (pt-PT)
PE (1) PE20142445A1 (pt-PT)
PH (1) PH12014502364A1 (pt-PT)
SG (1) SG11201407229UA (pt-PT)
UA (1) UA109867C2 (pt-PT)
WO (1) WO2013189862A1 (pt-PT)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140067048A (ko) 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
AU2014232383B2 (en) 2013-03-15 2019-01-17 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
SG11202005701VA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3218917A1 (en) * 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US8592402B2 (en) * 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
AU2011338561A1 (en) * 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
KR20140067048A (ko) * 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제

Also Published As

Publication number Publication date
AU2013279510A1 (en) 2014-10-16
BR112014031108A2 (pt) 2017-06-27
MX2014014105A (es) 2015-03-05
PE20142445A1 (es) 2015-01-28
EA201492283A1 (ru) 2015-04-30
WO2013189862A1 (en) 2013-12-27
PH12014502364A1 (en) 2015-01-12
EP2864294A1 (en) 2015-04-29
JP2015520201A (ja) 2015-07-16
CR20140516A (es) 2014-12-01
CO7160077A2 (es) 2015-01-15
SG11201407229UA (en) 2014-12-30
US20150259295A1 (en) 2015-09-17
HK1206341A1 (en) 2016-01-08
CN104411690A (zh) 2015-03-11
CL2014003242A1 (es) 2015-03-20
IL236091A0 (en) 2015-02-01
CA2869602A1 (en) 2013-12-27
KR20150011003A (ko) 2015-01-29
IN2014DN09347A (pt-PT) 2015-07-17
UA109867C2 (ru) 2015-10-12

Similar Documents

Publication Publication Date Title
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA35285B1 (fr) Indazoles
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA35576B1 (fr) Nouveaux composés
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA37929A1 (fr) Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch
MA54386B1 (fr) Modulateurs de trex1
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
EA201490618A1 (ru) Замещенные 2-(хроман-6-илокси)тиазолы и их пременение в качестве фармацевтических средств
MA38207A2 (fr) Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA45867B1 (fr) Modulateurs du récepteur des oestrogènes